Cerus Corporation (NASDAQ:CERS) announced today the promotion of
William "Obi" Greenman to the newly created position of President,
Cerus Europe, reporting to Claes Glassell, President and Chief
Executive Officer. Currently, Mr. Greenman serves as Cerus'
Vice-President, Business Development.
Effective immediately, Mr. Greenman will be responsible for
directing the European commercialization efforts for Cerus' lead
product, the INTERCEPT Blood System. The INTERCEPT Blood System for
platelets is currently on the market in Europe and the INTERCEPT Blood
System for plasma is currently pending review for CE mark approval.
"I am delighted that Obi has accepted this promotion," said Claes
Glassell, President and CEO of Cerus. "We are encouraged by the
progress of our commercialization of the INTERCEPT Blood System in
Europe, and Obi will add to the existing breadth of leadership in our
European headquarters."
Mr. Greenman will be leading a strong executive team that includes
Caspar Hogeboom, INTERCEPT Managing Director Cerus Europe and by Keith
Henderson, Vice-President, Manufacturing and Operations, both of whom
were appointed in March of 2006.
Mr. Greenman has an extensive experience base at Cerus, having led
business development, marketing and strategic planning activities for
more than a decade. In his role as VP of Business Development, Mr.
Greenman has been a key member of Cerus' management team. He led the
restructuring of the company's relationship with Baxter International,
structured the relationships with both BioOne and MedImmune and was
instrumental in establishing the Cerus European headquarters and
staffing the European organization. Prior to joining Cerus in 1995,
Mr. Greenman served in various corporate development and marketing
capacities for the Baxter Biotech Group, the biotech division of
Baxter International.
Mr. Greenman holds degrees in Biological Sciences and Economics
from Stanford University.
ABOUT CERUS
Cerus Corporation is a biopharmaceutical company that develops and
commercializes novel, proprietary products in the fields of blood
safety and immunotherapy to provide safer, more effective medical
options to patients in areas of substantial unmet medical needs. In
the field of immunotherapy, the company is employing its proprietary
attenuated Listeria vaccine platform to develop a series of novel
therapies to treat cancer, and it is applying its proprietary Killed
But Metabolically Active technology platform in research and
development of prophylactic and therapeutic vaccines for infectious
diseases. In the field of blood safety, the company is developing and
commercializing the INTERCEPT Blood System, which is based on the
company's proprietary Helinx technology and is designed to enhance the
safety of donated blood components by inactivating viruses, bacteria,
parasites and other pathogens, as well as potentially harmful white
blood cells. INTERCEPT, INTERCEPT Blood System and Helinx are
trademarks of Cerus Corporation.
